The global molecular diagnostics market is projected to reach USD 38.01 billion by 2034, according to a new report by Polaris Market Research. The study provides an in-depth assessment of market size, share, emerging trends, and growth forecasts from 2025 to 2034, highlighting the sector’s expanding role in modern healthcare.

Molecular diagnostics involves the application of advanced molecular biology techniques to detect genetic material, proteins, and other disease-specific biomarkers from patient samples. These technologies enable accurate diagnosis, prognosis, and disease monitoring, supporting the growing shift toward personalized and precision medicine. Demand has accelerated in recent years due to the increasing prevalence of infectious diseases, cancer, and genetic disorders, alongside the need for rapid and minimally invasive testing solutions.

Technological advancements such as digital polymerase chain reaction, next-generation sequencing, and microarray platforms are significantly improving test sensitivity, specificity, and turnaround time. At the same time, the integration of artificial intelligence and laboratory automation is enhancing workflow efficiency, minimizing manual errors, and strengthening clinical decision-making. The expansion of point-of-care molecular testing is also improving access to timely diagnostics, particularly in urgent and decentralized healthcare settings.

By product category, reagents and consumables account for the largest share of market revenue, reflecting the recurring demand generated by routine diagnostic workflows. Central laboratories continue to dominate testing volumes due to their advanced infrastructure and high-throughput capabilities. Regionally, North America holds the leading revenue share, supported by strong adoption of advanced molecular technologies and well-established healthcare systems. Meanwhile, the Asia Pacific region is expected to witness significant growth over the forecast period, driven by expanding healthcare investments, rapid technology uptake, and a rising burden of chronic and infectious diseases.

The competitive landscape features major global players including Abbott Laboratories, Agilent Technologies, Becton Dickinson, bioMérieux, Bio-Rad Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd, Grifols, Hologic Inc., Illumina Inc., QIAGEN, Siemens Healthineers AG, and Sysmex Corporation. Industry trends indicate growing emphasis on decentralized testing models, expansion of companion diagnostics for targeted therapies, and increasing collaboration between pharmaceutical and diagnostic companies.

With precision medicine reshaping healthcare delivery, the molecular diagnostics market is poised for sustained growth. Continued innovation, broader test portfolios targeting emerging pathogens, and digital health integration are expected to further accelerate adoption of fast, accurate, and scalable diagnostic solutions worldwide.